Phase II trial of Linsitinib (anti-IGFR/IR) in patients with relapsed and/or refractory Ewing Sarcoma

To determine the effect of the trial drug (linsitinib) on the patient�s tumours in terms of changes in biomarker and PET scans. To establish the safety of the trial drug (linsitinib) in Ewing sarcoma at the dose and treatment schedule being used in the trial.